Thiopurine Prodrugs Mediate Immunosuppressive Effects by Interfering with Rac1 Protein Function

Area of Science:

• Molecular Biology
• Immunology
• Pharmacology

Background:

• 6-Thiopurine (6-TP) prodrugs, including 6-thioguanine and azathioprine, are crucial in treating autoimmune disorders and cancers.
• Understanding the precise molecular mechanisms of 6-TP is essential for optimizing therapeutic strategies and minimizing side effects.

Purpose of the Study:

• To elucidate the molecular mechanism by which 6-thiopurine prodrugs exert their T-cell-specific immunosuppressive effects.
• To investigate the interaction of 6-TP metabolites with Rho GTPases, particularly Rac1, in activated T-cells.

Main Methods:

• Investigated the conversion of 6-TP to 6-thioguanosine triphosphate (6-TGTP) in T-cells.
• Analyzed the formation of disulfide adducts between 6-TGTP and the redox-sensitive motif of Rac1.
• Assessed the impact of RhoGAP and RhoGEF on the stability of the 6-TGTP-Rac1 adduct.

Main Results:

• 6-TGTP forms a stable disulfide adduct with Rac1 via its GXXXXGK(S/T)C motif in T-cells.
• The adduct formation inhibits guanine nucleotide exchange, leading to the accumulation of inactive Rac1.
• Rac1 is identified as the primary target of 6-TP in activated T-cells, explaining its immunosuppressive action.

Conclusions:

• 6-TP's therapeutic efficacy in autoimmune disorders stems from T-cell-specific inactivation of Rac1.
• This mechanism provides a basis for designing novel Rac1-targeting chemotherapeutic agents.
• Potential off-target effects on other Rho GTPases like RhoA in vascular cells may contribute to cytotoxicity.